Skip to main content
SpringerLink
Log in

Casodex: Preclinical Studies

  • Conference paper
Antiandrogens in Prostate Cancer

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

The established treatment for prostate cancer is endocrine manipulation since the growth of a majority of prostate tumours is stimulated by the male sex hormones, androgens. Thus, effective withdrawal of androgen by orchidectomy or oestrogen therapy has been the major form of treatment for prostate cancer for several decades. Orchidectomy is unpopular with patients, causes a loss of libido and can result in psychological trauma; since it is ineffective in about one quarter of patients they will have been submitted to unnecessary surgery. Although oestrogen therapy is effective in a majority of patients it is associated with unacceptably high morbidity and mortality, apparently due to cardiovascular complications, so survival is not increased [1]. As well as increasing the incidence of thromboembolism and causing fluid retention, oestrogen treatment also leads to the development of painful and embarrassing gynaecomastia and a loss of libido [2,3].

Casodex and Zoladex are trade marks of ZENECA Limited

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Veterans Administration Co-operative Urological Group: Treatment and survival of patients with cancer of the prostate. Surg Gynaecol Obstet 1967 (124): 1011–1017

    Google Scholar 

  2. Robinson MRG: Cancer of the prostate: Hormonal therapy. Clin Oncol 1982 (1): 233–244

    Google Scholar 

  3. Neumann F and Jacobi GH: Antiandrogens in tumour therapy. Clin Oncol 1982 (1): 41–65

    CAS  Google Scholar 

  4. Dutta AS and Furr BJA: Luteinizing hormone releasing hormone (LHRH) analogues. Ann Rep Medicinal Chemistry 1985 (20): 203–214

    Article  CAS  Google Scholar 

  5. Furr BJA and Milsted RAV: LH-RH analogues in cancer treatment. In: Stoll B (ed) Endocrine Management of Cancer. 2. Contemporary Therapy. Karger, Basel 1988 pp 16–29

    Google Scholar 

  6. Debruyne FMJ, del Moral PF, Geboers ADH: LHRH analogues therapy for metastatic prostate cancer. Progress Clin Biol Res 1988 (260): 27–39

    CAS  Google Scholar 

  7. Furr BJA and Hutchinson F: Biodegradable sustained release formulation of the LH-RH analogue ‘Zoladex’ for the treatment of hormone-responsive tumours. EORTC Genitourinary Group Monograph 2, Part A. Therapeutic Principles in Metastatic Prostatic Cancer. Alan R Liss, New York 1985 pp 143-153

    Google Scholar 

  8. Crawford D and Nabors W: Hormone therapy of advanced prostate cancer: Where we stand today. Primary Care and Cancer 1991 (11): 13–20

    Google Scholar 

  9. Janknegt RA, Abbou CC, Bartoletti R et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993 (149): 77–83

    PubMed  CAS  Google Scholar 

  10. Paisey RB, Kadow C, Bolton C, Hartog M and Gingell JC: Effects of cyproterone acetate and a long acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate. J Royal Soc Med 1986 (79): 210–211

    CAS  Google Scholar 

  11. Seed M, Godsland IF, Wynn V et al: The effects of cyproterone acetate and ethinyl estradiol on carbohydrate metabolism. Clin Endocrinol 1984 (21): 689–699

    Article  CAS  Google Scholar 

  12. Harris AL and Cantwell BMJ: Side-effects of endocrine therapies used to treat breast and prostate cancer. Clin Oncol 1985 (4): 511–533

    Google Scholar 

  13. McFarlane JR and Tolly DA: Flutamide therapy for advanced prostate cancer: a phase II study. Br J Urol 1985 (57): 172–174

    Article  Google Scholar 

  14. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Bluemenstein DA, David MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989 (321): 419–424

    Article  PubMed  CAS  Google Scholar 

  15. Lund F and Rasmussen F: Flutamide versus stilboestrol in the management of advanced prostate cancer. Br J Urol 1988 (61): 140–142

    Article  PubMed  CAS  Google Scholar 

  16. Katchen B and Buxbaum S: Disposition of a new, non-steroid, antiandrogen α,α,α trifluoro-2-methyl-4-nitro-m-propionotoluidide (flutamide) in men following a single oral 200 mg dose. J Clin Endocrinol Metabol 1975 (41): 371–373

    Article  Google Scholar 

  17. Tremblay D, Dupont A, Meyer BJ, Pottier J: The kinetics of antiandrogens in humans. In: Murphy GP, Khoury S, Kuss R, Chatelain C and Denis L (eds): Prostate Cancer A: Research into Endocrine Treatment and Histopathology. Alan R Liss, New York 1987 pp 345–350

    Google Scholar 

  18. Ojasoo J: Nilutamide. Drugs of the Future 1987 (12): 763–770

    Google Scholar 

  19. Harnois C, Malenfant M, Dupont A, Labrie F: Ocular toxicity of Anandron in patients treated for prostate cancer. Br J Ophthalmol 1986 (70): 471–473

    Article  PubMed  CAS  Google Scholar 

  20. Brisset JM, Bertagna L, Proulx L: Ocular toxicity of Anandron. Br J Ophthalmol 1987 (71): 639

    Article  PubMed  CAS  Google Scholar 

  21. Furr BJA, Valcaccia B, Curry B et al: ICI 176,334: A novel non-steroidal, peripherally selective antiandrogen. J Endocrinol 1987 (113): R7–R9

    Article  PubMed  CAS  Google Scholar 

  22. Winneker RC, Wagner MM, Batzold FH: Studies on the mechanism of action of Win 49,596: a steroidal androgen receptor antagonist. J Steroid Biochem 1989 (33): 1133–1138

    Article  PubMed  CAS  Google Scholar 

  23. Fuhrmann U, Bengston C, Repenthin G, Schillinger E: Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: inhibition of CAT expression by antiandrogens. J Steroid Biochem 1992 (42): 787–793

    Article  CAS  Google Scholar 

  24. Juniewicz RE, McCarthy M, Lemp BM, Barbolt TA, Shaw C, Hollenbaugh DM, Winneker RC, Reel JR, Batzold FH: The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of Beagle dogs. Endocrinology 1990 (126): 2625–2634

    Article  PubMed  CAS  Google Scholar 

  25. Ayub M and Levell MJ: The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5-dihydrotestosterone and [3H]cortisol binding to plasma proteins. J Steroid Biochem 1989 (33): 251–255

    Article  PubMed  CAS  Google Scholar 

  26. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GGJM, Jenster G, Trapman J, Brinkman AO, Mulder E: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem 1992 (41): 665–669

    Article  CAS  Google Scholar 

  27. Freeman SN: Studies on the mechanism of action of a novel, non-steroidal antiandrogen, ICI 176,334. Ph D Thesis, University of Leeds 1988 pp 109-115

    Google Scholar 

  28. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E: Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction and transcription activation. Biochemistry 1992 (31): 2393–2399

    Article  PubMed  CAS  Google Scholar 

  29. Kelly WK and Scher H: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993 (149): 607–609

    PubMed  CAS  Google Scholar 

  30. Dupont A, Gomez J-L, Cusan L, Koutsilieris M, Labrie F: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993 (150): 908–913

    PubMed  CAS  Google Scholar 

  31. Darbre PD and King RJB: Steroid hormone regulation of cultured breast cancer cells. In: Lippman ME and Dickson R (eds) Breast Cancer and Molecular Biology. Kluwer Academic, Boston 1988 pp 307–341

    Chapter  Google Scholar 

  32. Darbre PD and King RJB: Antiandrogen ICI 176,334 does not prevent development of androgen insensitivity in S 115 mouse mammary tumour cells. J Steroid Biochem 1990 (36): 385–389

    Article  PubMed  CAS  Google Scholar 

  33. Snyder BW, Winneker RC, Batzold FJ: Endocrine profile of Win 49,596 in the rat: a novel androgen receptor antagonist. J Steroid Biochem 1989 (33): 1127–1132

    Article  PubMed  CAS  Google Scholar 

  34. Chandolia RK, Weinbauer GF, Behre HM, Nieschlag EL: Evaluation of a peripherally selective antiandrogen (‘Casodex’) as a tool for studying the relationship between testosterone and spermatogenesis in the rat. J Steroid Biochem 1991 (38): 367–375

    Article  CAS  Google Scholar 

  35. Chandolia RK, Weinbauer GF, Simoni M, Behre HM, Nieschlag E: Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and ‘Casodex’ on the reproductive system of the adult male rat. Acta Endocrinologica 1991 (125): 547–555

    PubMed  CAS  Google Scholar 

  36. Simoni M, Weinbauer GF, Chandolia RK, Nieschlag E: Microheterogeneity of pituitary follicle-stimulating hormone in male rats: differential effects of the chronic androgen deprivation induced by castration or androgen blockade. J Mol Endocrinol 1992 (9): 175–182

    Article  PubMed  CAS  Google Scholar 

  37. Belchetz PE: Effects of androgens and antiandrogens on pulsatile gonadotrophin-releasing hormone secretion from the adult male rat hypothalamus in vitro. J Endocrinol 1987 (115 suppl): abstr 59

    Google Scholar 

  38. Freeman S N, Mainwaring WIP, Furr BJA: A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, ‘Casodex’ (ICI 176,334). Br J Cancer 1989 (60): 664–668

    Article  PubMed  CAS  Google Scholar 

  39. Labrie F, Dupont A, Belanger A: Complete androgen blockade for the treatment of prostate cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. Lipincott, Philadelphia 1985 pp 193–200

    Google Scholar 

  40. Hutchinson FG and Furr BJA: Biodegradable polymers for the sustained release of peptides. Biochem Soc Transactions 1985 (13): 520–523

    CAS  Google Scholar 

  41. Blackledge GRP: Clinical aspects of Casodex. Chapter in this Monograph

    Google Scholar 

  42. Eri LM and Tveter KJ: A prospective, placebocontrolled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol 1993 (150): 90–94

    PubMed  CAS  Google Scholar 

  43. Jones HB, Betton GR, Bowdler AL, McFarquahar BJ, Middleton BJ, Lunglmayr G: Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchiectomy. Urol Res 1994 (in press)

    Google Scholar 

  44. McClain RM: The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid neoplasia. Toxicol Pathol 1989 (17): 294–306

    Article  PubMed  CAS  Google Scholar 

  45. McClain RM: Mouse liver tumours and microsomal enzyme-inducing drugs: experimental and clinical perspectives with phenobarbital. In: Stevenson DE, McClain RM, Popp JA, Slaga TJ, Ward JM and Pitot HC (eds) Mouse Liver Carcinogenesis: Mechanisms and Species Comparisons. Alan R Liss, New York 1990 pp 345–365

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vascular, Inflammatory and Musculoskeletal Research Department, ZENECA Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK

    Barry J. A. Furr

Authors
  1. Barry J. A. Furr
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oncologisch Centrum Antwerpen, Algemeen Ziekenhuis Middelheim, Vrije Universiteit Brussel, Lindendreef 1, 2020, Antwerp, Belgium

    Louis Denis

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Furr, B.J.A. (1996). Casodex: Preclinical Studies. In: Denis, L. (eds) Antiandrogens in Prostate Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45745-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45745-6_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45747-0

  • Online ISBN: 978-3-642-45745-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation